Targeting tumor hypoxia with hypoxia-activated prodrugs

Journal of Clinical Oncology

Volumn 33, Issue 13, 2015, Pages 1505-1508

  Yeh, Jen Jen ^a   Kim, William Y ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTRIAZINE N OXIDE DERIVATIVE; EVOFOSFAMIDE; GEMCITABINE; HYPOXIA ACTIVATED PRODRUG; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN; PR 104A; SN 30000; TIRAPAZAMINE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR HYPOXIA; HUMAN; MALE; PANCREATIC NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84929416830     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.0759     Document Type: Article

References (41)

1. Ryan DP, Hong TS, Bardeesy N: Pancreatic adenocarcinoma. N Engl J Med 371:1039-1049, 2014
2. Provenzano PP, Hingorani SR: Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 108:1-8, 2013
3. Koong AC, Mehta VK, Le QT, et al: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48:919-922, 2000
4. Rhim AD, Oberstein PE, Thomas DH, et al: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25:735-747, 2014
5. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
6. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719-734, 2014
7. Borad MJ, Reddy SG, Bahary N, et al: Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol [epub ahead of print on December 15, 2014]
8. Patterson AV, Ferry DM, Edmunds SJ, et al: Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 13:3922-3932, 2007
9. Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 8:967-975, 2008
10. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410, 2003
11. Vaupel P: Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. Oncologist 13:21-26, 2008
12. Kim WY, Kaelin WG Jr: Molecular pathways in renal cell carcinoma: Rationale for targeted treatment. Semin Oncol 33:588-595, 2006
13. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004, 2004
14. Bristow RG, Hill RP: Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192, 2008
15. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
16. Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51-56, 2010
17. Gilkes DM, Semenza GL, Wirtz D: Hypoxia and the extracellular matrix: Drivers of tumour metastasis. Nat Rev Cancer 14:430-439, 2014
18. McDonough MA, Loenarz C, Chowdhury R, et al: Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struct Biol 20:659-672, 2010
19. Cramer T, Yamanishi Y, Clausen BE, et al: HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645-657, 2003
20. Palazon A, Goldrath AW, Nizet V, et al: HIF transcription factors, inflammation, and immunity. Immunity 41:518-528, 2014
21. Dang EV, Barbi J, Yang HY, et al: Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146:772-784, 2011
22. Wilson WR, Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393-410, 2011
23. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
24. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): A phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
25. Williamson SK, Crowley JJ, Lara PN Jr, et al: Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23:9097-9104, 2005
26. Hicks KO, Pruijn FB, Secomb TW, et al: Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxiatargeted anticancer drugs. J Natl Cancer Inst 98:1118-1128, 2006
27. Reference deleted
28. Keith B, Simon MC: Hypoxia-inducible factors, stem cells, and cancer. Cell 129:465-472, 2007
29. Saggar JK, Tannock IF: Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer 134:2726-2734, 2014
30. Trédan O, Garbens AB, Lalani AS, et al: The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res 69:940-947, 2009
31. Primeau AJ, Rendon A, Hedley D, et al: The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11:8782-8788, 2005
32. Lankelma J, Dekker H, Luque FR, et al: Doxorubicin gradients in human breast cancer. Clin Cancer Res 5:1703-1707, 1999
33. Tatum JL, Kelloff GJ, Gillies RJ, et al: Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82:699-757, 2006
34. Öhlund D, Elyada E, Tuveson D: Fibroblast heterogeneity in the cancer wound. J Exp Med 211:1503-1523, 2014
35. Risbridger GP, Davis ID, Birrell SN, et al: Breast and prostate cancer: More similar than different. Nat Rev Cancer 10:205-212, 2010
36. Chawla SP, Cranmer LD, Van Tine BA, et al: Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol 32:3299-3306, 2014
37. Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117, 2010
38. Mathew E, Zhang Y, Holtz AM, et al: Dosage-dependent regulation of pancreatic cancer growth and angiogenesis by hedgehog signaling. Cell Rep 9:484-494, 2014
39. Lee JJ, Perera RM, Wang H, et al: Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci 111:E3091-E3100, 2014
40. Sherman MH, Yu RT, Engle DD, et al: Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159:80-93, 2014
41. Vaupel P, Mayer A, Briest S, et al: Oxygenation gain factor: A novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 63:7634-7637, 2003